Thanks for the update, been meaning to check that.

After the last run, I am now even more unsure of future action we have in store for us in the short term.

Im going to get in contact with IR soon, Craig, or anyone else here, if you want to PM me your email and we can set up a way to communicate outside of the app, and I can keep you in the loop on what I hear and ask, plus I would love to over time develop an email list of sorts with other familiar shareholders here to communicate and share inputs, without the biases and lies present in board chatter.

Cheers!

The Exciting Story of Endonovo Therapeutics Inc (OTCMKTS: ENDV)

"Disclosure: we hold no position in ENDV either long or short and we have not been compensated for this article."

https://www.microcapdaily.com/the-exciting-story-of-endonovo-therapeutics-inc-otcmkts-endv/121621/

Watching ENDV's Level 2 can be more entertaining than TV. Looked like a long dumped some shares, scared it was gonna plummet, but now ASCM has backed off to 0.054, and back up we go?

I wish the million share bid support that was present last week would pop back up, but either way still nice to see continued volume with pretty even buy/sells so far.

Definitely not surprising, we know these things take time. I think its cool that they have all of their patients enrolled from the looks of it, says starting date as of tomorrow.

Either way, as Bro said, haven’t seen this kind of movement really ever here. Even on the first run it was not like this. Something is happening that has not happened before, and my eyes are peeled.

Have a great holiday weekend everyone!

This was posted TODAY, just came across.

https://clinicaltrials.gov/ct2/show/NCT03654014

Best post of the day LOL

I have averaged down the entire time. Screwed up hard buying up to 0.09 on the first run early to mid last year, and have gotten my average successfully down to around 0.05 since then. Its been incredibly hard to do, and especially this most recent crash with the A/S news. But I have way too much money in here to sell for that much of a loss. Ive treated this as a huge learning experience, becoming a much more patient trader because of this, but have always felt that the PPS would eventually, at the bare minimum, reach my average, with the potential to do much more. Its always been a risk, but there have been certain factors that have still kept me cautiously optimistic for the future.

Still wish I never bought until a couple months ago, would had four times the amount of shares lol

This run is incredibly unique, no board chatter or Breakout board at play, articles couldn’t have brought this sustained buying volume since Friday. No clue honestly. Haven’t seen this kind of movement up since I first bought shares at 0.03 in March of last year.

Patience

Its nice to see over a million down at 0.03 too. I think many of us who have watched this daily for some time can agree we haven’t had this kind of positive level 2 action in a while. Definitely a nice sight.

Wow you didn’t get a chance to load before this run it appears, huh?

https://finance.yahoo.com/news/cannabis-biotech-stocks-high-alert-143000976.html

Nice ask slaps today, I’m not seeing things right? lol

Cheers Craig, beat me to it. Your on the night shift, ill be back on it in 8 hours LOL

Looking for cheap shares tomorrow, huh?

Tell me the last day we had 4.5 million volume in the first hour

Its far from over... bud. See you here in a week on the next run

LOL looks like a lot of people trying to get some shares today...

Haha hell yeah shut up all of you. There we go

Tomorrow’s going to be a big volume day, that’s for sure. ENDV is an arbitrary opportunity

10-Q out

He is responsive to me and is much more detailed than Steve ever was, so I cant complain, why do you say that?

Ah come on which “long” just put their 200k on the ask

In my email conversation with Andrew last week, it was confirmed that no RS is planned at this time as it would be completely against their long-term strategy to increase shareholder value.

Seems like a bad time to sell in my opinion with the incoming quarterly that we can almost guarantee more revenue from Sofpulse, plus any other updates. I think many felt this was a quicker process, as I did myself when I first bought over a year and a half ago, but doesn’t detract from the long term potential here to be bigger than any of us can possibly render. So many people hate the lack of updates, but id much rather have this than pump PR’s. But either way, I cant help but feel the price will bounce back, and I personally wouldn’t sell at this time.

Even if out of know where they initiated a RS Which many ppl here fear, along with some news, the pps would still arise more than it is now even with a split. Point is, We are at an incredible low and I don’t foresee us longs never having a chance to sell again for profit. If anything, i still think we are due for a huge move just with our assets alone and pipeline and potential to be bought out, and if we can ever figure out who the hell is solely destroying this stock via shorting and manipulating it. Could literally be someone here wanting cheaper shares, as others have mentioned before. Or a big institution, none the less, dilution isn’t doing this to our PPS, and we are set up for some big catalysts in next 2 years.

Hence why my personal 800k + shares aren’t going anywhere.

Literally 560k shares between .0294 - .0295

Thats why I am honestly not incredibly worried. This is getting mm shorted and pushed down harder than ever before, yet nobody is focusing in on this now. Many think its dilution or what not, but as you said, when watching level 2 its obvious whats happening right now

NEW ARTICLE out today - Bill Gates Dedicates $30M into Alzheimer’s Treatments

HENDERSON, NV / ACCESSWIRE / July 23, 2018 / Along with several other philanthropists, Bill Gates recently announced he is putting $30 million into the Diagnostics Accelerator, a “venture philanthropy” fund to develop early diagnostic procedures and bring them to market quickly.

One small Alzheimer related biotech firm on our radar is Endonovo Therapeutics, Inc. (ENDV). ENDV could be just one little push from a massive inflection point. This company has traded well over 300% higher in the last year. There was a massive rush into ENDV last October, and smart, risk tolerant investors could take advantage of this opportunity.

Gates hopes to get Alzheimer’s patients diagnosed earlier.

Alzheimer’s is a brain disease that affects memory, motor functions, and eventually, a person’s ability to function properly in daily life. If you live to 85 – which is not uncommon in the modern world – you have a one-third chance of developing the disease, according to the Alzheimer’s Association. As the US population ages, the disease is expected to affect 13.8 million by 2050.

At the beginning of the year, several companies started giving up on treating the disease. However, many still remain in the space, and could benefit from Gates’ crusade against the disease.

Endonovo Therapeutics, Inc. (ENDV)

Market cap: $11.649 million; current share price: $0.0332

Endonovo Therapeutics, Inc. (ENDV), a commercial-stage developer of Electroceutical™ Therapies, recently announced that the first patient has been enrolled in a clinical study at the University of New Mexico Health Sciences Center that will evaluate the effects of Pulsed Electromagnetic Fields (PEMF) on reducing brain injury, blood-brain-barrier and inflammation biomarkers in the cerebrospinal fluid and blood in patients with brain injury who are or have been fitted to an external ventricular drain. Funding for the study has been secured via the Company’s senior secured Series C Preferred Stock financing.

“The initiation of this study represents a significant milestone for Endonovo,” said Endonovo CEO, Alan Collier. “We believe our technology, whose proven mechanism of action is the suppression of inflammation, has the potential to change the treatment of central nervous system disorders where neuroinflammation propagates injury such as ischemic stroke, Alzheimer’s disease and Multiple Sclerosis.”

http://www.wmcactionnews5.com/story/38706520/bill-gates-dedicates-30m-into-alzheimers-treatments

Lol these guys are entertaining for sure

You have no idea what a bad day even remotely looks like here lol

And another one...

Wondering why they haven't tweeted these yet, also posted today.

Biotech Companies with Great Futures

HENDERSON, NV / ACCESSWIRE / July 16, 2018 / One company that comes to mind when you consider the endless possibilities in biotech, is none other than Endonovo Therapeutics Inc. (ENDV). ENDV is 400% off of it's 52 week-high, and could be gearing up for a strong turn around at any moment.

Endonovo Therapeutics, Inc. is a commercial-stage developer of non-invasive wearable Electroceuticals™. The Company's current portfolio of commercial and clinical-stage wearable Electroceuticals™ addresses wound healing, pain, post surgical edema and Central Nervous System (CNS) Disorders, including traumatic brain injury (TBI), acute concussions, post-concussion syndrome and multiple sclerosis.

The Company's non-invasive Electroceutical device using pulsed short-wave radiofrequency at 27.12 MHz has been FDA-Cleared and CE Marked for the palliative treatment of soft tissue injuries and post-operative pain and edema, and has CMS National Coverage for the treatment of chronic wounds. The Company's current portfolio of pre-clinical stage Electroceuticals addresses chronic kidney disease, liver disease, cardiovascular and peripheral artery disease. The Company's non-invasive, wearable Electroceuticals work by restoring key electrochemical processes that initiate anti-inflammatory and growth factor cascades necessary for healing to occur.

Most recently Endonovo announced (1) Enrollment of its First Patient in a Clinical Study at the University of New Mexico for Treating Traumatic Brain Injury Using Its Electroceutical Therapy, (2) a Distribution Agreement with Plagens Medical Consultants for its Pain Relief Electroceutical SofPulse, (3) Highlighted the Feasibility Study Results of Its Electroceutical Therapy in Reducing Proteinuria in Chronic Kidney Disease Patients, and (4) plan to Conduct a Larger Clinical Study to Evaluate Its Electroceutical Therapy in Chronic Kidney Disease.

With Everything that ENDV has going for it, we are looking for a breakout in the near future.

https://finance.yahoo.com/news/biotech-companies-great-futures-144500769.html

There was actually an article today I just came upon.

HENDERSON, NV / ACCESSWIRE / July 16, 2018 / When it comes to biotech companies much of the immediate value lies in the speculation. This is because it can take several years for a biotech company to bring their drug or product to market. Considering these facts we have identified Endonovo Therapeutics, Inc. (ENDV) as our breakout stock of 2018.

Endonovo Therapeutics Inc. (ENDV)

Endonovo Therapeutics, Inc. is a commercial-stage developer of non-invasive wearable Electroceuticals™. The Company's current portfolio of commercial and clinical-stage wearable Electroceuticals™ addresses wound healing, pain, post surgical edema and Central Nervous System (CNS) Disorders, including traumatic brain injury (TBI), acute concussions, post-concussion syndrome and multiple sclerosis.

The Company's non-invasive Electroceutical device using pulsed short-wave radiofrequency at 27.12 MHz has been FDA-Cleared and CE Marked for the palliative treatment of soft tissue injuries and post-operative pain and edema, and has CMS National Coverage for the treatment of chronic wounds. The Company's current portfolio of pre-clinical stage Electroceuticals addresses chronic kidney disease, liver disease, cardiovascular and peripheral artery disease. The Company's non-invasive, wearable Electroceuticals work by restoring key electrochemical processes that initiate anti-inflammatory and growth factor cascades necessary for healing to occur.

Most recently Endonovo announced (1) Enrollment of its First Patient in a Clinical Study at the University of New Mexico for Treating Traumatic Brain Injury Using Its Electroceutical Therapy, (2) a Distribution Agreement with Plagens Medical Consultants for its Pain Relief Electroceutical SofPulse, (3) Highlighted the Feasibility Study Results of Its Electroceutical Therapy in Reducing Proteinuria in Chronic Kidney Disease Patients, and (4) plan to Conduct a Larger Clinical Study to Evaluate Its Electroceutical Therapy in Chronic Kidney Disease.


https://www.marketwatch.com/press-release/3-biotech-stocks-to-bet-on-in-the-second-half-of-2018-2018-07-16

VFIN???

I feel like many shareholders here are our own worst enemy. I understand sitting on the bid to get shares, as it literally almost always seems to work here, but when the entire base of shareholders has this mentality, it will be very hard to sustain any kind of movement in my opinion. Until WABR comes back or another institutional/big investor to truly give bid support or some phenomenal news comes, the buying support will not be there because every long knows sitting on the bid can get them cheaper shares.

Just another reason why watching the daily action here is somewhat useless. I cant help but feel WHEN our day does come, its not going to be the 100-300% gains most penny traders look for, its going to be a huge market valuation shift that will bring on so many new investors it will feel like a whole new company here. If management can even just manage to sustain the PPS where we sit at today in the 0.03-0.05 range while continuing to fund operations and everything else,its a no brainer within a couple years we will get huge news here. I know they get a lot of shit but in my opinion i definitely feel like management is doing a hell of a job at setting themselves up for long term success. Its a huge waiting game, i think they are doing their best at doing what they can now while not destroying the company’s share structure. I cant help but feel as long as everything stays status quo here, we are still looking damn good.

I think the reason you are getting hassle here is because there are a very tight group of shareholders here who have been on this board communicating for quite some time, almost a year and a half myself. As others have said, this board seems to be of some rarity compared to other OTC pennies in terms of the kind of content talked about, and the immense knowledge some shareholders here know about this field.

When very educational, weekend board talk is happening about future possibilities and different catalysts, and then a comment like yours gets mixed in during a rather informative discussion of this, you gotta understand your gonna get some backlash. Your relatively new to this board, and even though you say you’ve been a shareholder here for a long time as well, it seems you don’t know all that much about what the company your invested in actually has going on in terms of the details.

Next time, you could try to read through all the PR’s, shareholder letters and annual/quarterlies, before asking where a statement has come from. Just shows to others here that your a more diligent shareholder. Just little things like this id imagine will get you more respect here, instead of picking fights and bickering with trustworthy longs who are very trusted and appreciated here. Cheers

Literally want to give that person the biggest hug right now

It’s only bizarre if you haven’t been a shareholder for over a year LOL

The PR wast posted to Globenewswire the link is on twitter

Nice post Sello

Nice pickup bud. Cant believe it fell that low this AM. Just woke up